OmniAb, Inc. announced it will report financial results for the three and nine months ended September 30, 2026, before the open of the U.S. financial markets on Friday, October 30, 2026.

The company will hold a conference call to discuss these results and provide business updates on the same day at 8:00 a.m. Eastern time (5:00 a.m. Pacific time).

Conference Call Details

Investors and analysts can access the live webcast and replay via the links provided below. The dial-in details for the audio portion of the call are as follows:

About OmniAb

OmniAb licenses discovery research technology to pharmaceutical and biotech companies and academic institutions. The company’s platform creates and screens diverse antibody repertoires to identify optimal antibodies and target-binding proteins for drug development.

Key components of the OmniAb platform include:

• Biological Intelligence™: Powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates.
• xPloration: An AI-powered high-throughput single B-cell screening platform used to identify fully-human antibodies with exceptional performance and developability characteristics.

The company provides partners with integrated end-to-end capabilities and customizable offerings. Its business model aligns scientific and economic interests through structured agreements that generally include upfront/access fees, service revenue, milestones, and royalties on commercial sales.

OmniAb Inc. (NASDAQ: OABI) announced a global collaboration and license agreement with Eli Lilly & Company (NYSE: LLY) to advance a new ion channel program. The partnership leverages OmniAb’s proprietary technology platform and expertise in ion channel discovery and screening to address major unmet medical needs. Shares of OmniAb rose in premarket trading following the announcement, reflecting investor confidence in the deal’s potential economics.

Under the terms of the agreement, OmniAb will receive an undisclosed upfront payment. The company is also eligible to receive up to $370 million in research, development, and commercial milestone payments, along with tiered royalties on global net sales. The specific therapeutic target and modality for the program remain undisclosed.

Raised Cash Guidance

In conjunction with the deal, OmniAb raised its financial guidance for 2026. The company now expects to end the year with $49 million to $53 million in cash and cash equivalents. This represents a significant increase from its previous forecast of $37 million to $41 million, driven by recent technology licensing activity including the Lilly agreement.

Strong Q1 Revenue Context

The Lilly agreement arrives after OmniAb reported a strong first quarter in which revenue reached $14.4 million, compared with $4.2 million a year earlier, largely reflecting milestone revenue. Earlier company disclosures showed 107 active partners and 409 active programs, with 98% of those programs carrying contracted future economics and more than $3 billion in contracted milestones.

Strategic Alignment

Matt Foehr, OmniAb’s Chief Executive Officer, stated that the relationship aligns with Lilly’s focus on delivering medicines for significant unmet medical needs. He noted that OmniAb’s differentiated expertise and established technologies related to ion channels are well-positioned to drive this new discovery program.

OmniAb licenses cutting-edge discovery research technology to pharmaceutical companies, biotech firms, and academic institutions. Its platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins. The core of the platform is Biological Intelligence™, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

The company’s suite of technologies includes computational antigen design, immunization methods, high-throughput single B-cell phenotypic screening, and mining of next-generation sequencing datasets using custom algorithms. These methods aim to identify fully-human antibodies with exceptional performance and developability characteristics. OmniAb’s business model typically involves structured agreements including upfront fees, service revenue, milestones, and royalties on commercial sales.

Market Reaction

OmniAb shares were up 18.34% at $4.00 during premarket trading. The stock traded above its prior 52-week high of $3.63. Technical indicators showed the stock trading 65.9% above its 20-day SMA and 107.6% above its 200-day SMA. The Relative Strength Index (RSI) stood at 80.20, indicating overbought conditions.

What the Numbers Show

The Lilly deal potentially reinforces the idea that OABI is becoming a biotech picks-and-shovels platform rather than a conventional single-asset biotech. While the $370 million headline is contingent, the pharmaceutical validation is real. The risk remains that milestones are contingent, programs can fail and royalty economics depend on successful commercialization.